Product line for early-stage drug discovery streamlines the development of molecular tools to allow rapid screening against targets without costly in-housde sequencing
The new Cytomyx product line, Cytobank, is now available in the UK and Ireland from Cambridge BioScience.
Cytobank is an important collection of new biological tools designed to accelerate early-stage drug discovery.
At present in the pharmaceutical industry, many companies expend considerable resources investigating similar cDNA targets, and independently developing the molecular tools to investigate novel compounds. Cytobank streamlines this process, enabling clients to rapidly screen against any of its targets without the need for costly in-house sequencing.
Cytobank uniquely compiles more than 250 important pharmaceutical targets, including key compound targets such as G-protein coupled receptors, ion channels, and kinases. Most products within the Cytobank range are full-length cDNAs to be used for target validation, assay development, high-throughput screening, and counter-screening.
All the sequences are relevant drug targets, and many are particularly difficult to isolate in-house due to their sequence length, complexity and rarity. Cytomyx plans to expand Cytobank to include many recombinant proteins, validated cell lines, antibodies, and other essential molecular tools to simplify the target validation stage of target selection-a current bottleneck within the industry.
These products are available from Cambridge BioScience in the UK and Ireland only.
